This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002’s potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in ...

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology's Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accept ...

Haemonetics (HAE) has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics' Plasma business continues to grow, banking on an expanding end-user market for plasma-derived biopharmaceuticals. In the second quarter of 2024, U.S. collection volume growth was robust. Both North America software and Europe disposable revenues witnessed double-digit ...

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE) NTLA-2002 is Intellia's second in vivo candidate to enter late-stage clinical development from its modular gene editing platform CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the initiation ...

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows: Title: Long-Term ...

Haemonetics Corporation (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company's Hemostasis Management franchise is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism. Meanwhile, headwinds from adverse foreign exchange effects pose concern to Haemonetics' operations. In the past year, this Zacks Rank #2 (Buy) company has lost 14.5% against the industry's 24.6% growth an ...

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be pr ...

Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support the potential for deucrictibant to become a preferred therapy for the management of HAE Long-term prophylaxis extension data of deucrictibant shows attack reduction is maintained for over one year; open-label extension participants experienced a 93% reduction in attacks compared to baseline Long-term on-demand extension data of deucrictibant immediate-release capsule shows median onset of symptom rel ...